Trial reportDrug design, development and therapy2026
Remimazolam Reduces the Cough Reflexes in Elderly Patients Undergoing Fiberoptic Bronchoscopy Under Remifentanil/Cipepofol-Based Anaesthesia: A Randomized Clinical Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fiberoptic bronchoscopy (FOB) is one of the most common critical procedures for diagnosis and treatment of respiratory diseases. We aimed to determine whether remimazolam reduces the cough reflexes in patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Methods: This was a single-center, single-blinded, randomized study. We included 90 adult patients underwent FOB with ASA I-III, aged 60-90 years. Patients were randomly assigned to cipepofol (CIP) group or remimazolam-cipepofol (RMZ-CIP) group. In the CIP group, anaesthesia was induced sequentially with remifentanil and cipepofol. In the RMZ-CIP group, anaesthesia was induced sequentially with remifentanil, remimazolam, and cipepofol. A laryngeal mask airway (LMA) was inserted in both groups when the BIS ≤ 60. Anaesthesia was maintained with remifentanil and cipepofol with a BIS value between 40 and 60. The primary outcome was the incidence and severity of cough reflexes during the first FOB. The secondary outcomes included vital signs, characteristics of FOB and anaesthesia, administration of vasoactive drugs, and adverse events. Results: The incidence of cough reflexes during FOB was lower in the RMZ-CIP group than that in the CIP group (38% vs 62%, Conclusion: The combination of remimazolam reduced the incidence of cough reflexes and dosage of cipepofol and remifentanil in elderly patients undergoing FOB under remifentanil/cipepofol-based anaesthesia. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2300079139).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.